PROTEUS May Mean New SOC for Some Prostate Cancers.
- In the news
Adding apalutamide to androgen deprivation therapy improves 5-year metastasis-free survival to 78.2% in high-risk localized prostate cancer patients.
- Why it matters: This finding addresses the need for more effective treatments to prevent metastasis and death in high-risk prostate cancer, a critical gap in current management strategies.
- What they did: The phase III PROTEUS trial compared 6 months of apalutamide plus ADT versus perioperative ADT alone in patients undergoing surgery, with 5-year follow-up data.
- The result: Patients receiving apalutamide plus ADT showed a significant increase in metastasis-free survival, enabling improved long-term outcomes and potential new standards of care.